Woman & Home on MSN
A 'vital' new drug for hot flushes is now available: What does this mean for UK women?
Veoza, also known as fezolinetant, was first approved a couple of years ago - and is now available for prescription for those ...
Nordot on MSN
IVF not linked to overall cancer risk in massive study – but one late-life danger still can't be ruled out
A vast Australian study of 417,984 women finds fertility treatment does not raise overall cancer rates. But subtle tumour shifts and one key uncertainty keep doctors cautious. Fertility drugs, hormone ...
Jennifer Lopez presents Kerry Washington with the Courage Award at the Women’s Cancer Research Fund’s An Unforgettable Evening gala in Beverly Hills. (Stefanie Keenan/ for Women's Cancer Research Fund ...
Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...
In this video, Rebecca Stone, MD, MS, discussed highlights in ovarian cancer from Society of Gynecologic Oncology 2026 Winter ...
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous ...
Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous ...
High-grade serous ovarian cancer is the most common and aggressive form of ovarian cancer and often becomes resistant to ...
The pembrolizumab regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared with placebo plus paclitaxel with or without bevacizumab. The Food and ...
A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...
FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials. The FDA has approved pembrolizumab (Keytruda) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results